Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 1228Lung Neoplasms 560Colorectal Neoplasms 282Breast Neoplasms 257Neoplasms 254Melanoma 236Small Cell Lung Carcinoma 234Ovarian Neoplasms 234Pancreatic Neoplasms 186Squamous Cell Carcinoma of Head and Neck 171Neoplasm Metastasis 171Carcinoma, Renal Cell 164Stomach Neoplasms 158Triple Negative Breast Neoplasms 127Head and Neck Neoplasms 121Esophageal Neoplasms 115Prostatic Neoplasms 106Urinary Bladder Neoplasms 105Colonic Neoplasms 95Uterine Cervical Neoplasms 93Endometrial Neoplasms 93Mesothelioma 84Mesothelioma, Malignant 79Carcinoma, Hepatocellular 78Sarcoma 70Carcinoma, Transitional Cell 69Kidney Neoplasms 65Carcinoma, Ovarian Epithelial 50Adenocarcinoma of Lung 47Rectal Neoplasms 45

Interventions

osimertinib 1cemiplimab 1Vascular Endothelial Growth Factor A 1Paclitaxel 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lethal Congenital Contracture Syndrome 2 × Thoracic × Clear all
NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡